CORSYM
LOE ApproachingNDAORALSUSPENSION, EXTENDED RELEASE
Approved
Jan 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CORSYM is an oral extended-release suspension approved in 1984 by UCB Pharma as a small-molecule NDA product. The mechanism of action and therapeutic indications are not publicly disclosed in available data. This is a legacy product with significant historical approval longevity.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching, suggesting smaller brand team and focus on retention and managed decline strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's late-lifecycle stage and anticipated LOE. Roles available are primarily defensive/retention-focused rather than growth-oriented, with emphasis on managed decline and compliance.
Brand ManagerField Sales Representative
Worked on CORSYM at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.